A multicenter, prospective, non-interventional observational study to determine LDL-C goal attainment rate in elderly patients with dyslipidemia receiving Mevalotin® Tab.
Not Applicable
Completed
- Conditions
- Endocrine, nutritional and metabolic diseases
- Registration Number
- KCT0003190
- Lead Sponsor
- Daiichi-Sankyo Korea
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
1. Males or females aged = 65 years with a diagnosis of dyslipidemia
2. Patients who were prescribed Mevalotin® in the judgment of their physicians, or who started receiving Mevalotin® tab. within 6 weeks from enrollment in this observational study
3. Voluntary written consent to participation in this observational study by the patients or their representatives
Exclusion Criteria
There will be no particular exclusion criteria.
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of subjects who attain the LDL-C goal defined in the 2015 Korean Guidelines for Management of Dyslipidemia after the administration of Mevalotin® tab. for 24 weeks in elderly patients
- Secondary Outcome Measures
Name Time Method Incidence of Adverse Events and Adverse Drug Reactions;The proportion of subjects who attain the non-HDL-C goal defined in the 2015 Korean Guidelines for Management of Dyslipidemia after the administration of Mevalotin® tab. for 24 weeks in elderly patients;Percent change from baseline in the blood non-HDL-C at Week 24;Percent change from baseline in the blood LDL-C at Week 24;Percent change from baseline in the total blood cholesterol at Week 24;Percent change from baseline in the blood HDL-C at Week 24;Percent change from baseline in the blood triglycerides at Week 24